GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential

https://www.news-medical.net/health/GLP-1-receptor-agonists-in-Alzheimere28099s-disease-Emerging-off-label-neuroprotective-potential.aspx From reduced amyloid and neuroinflammation in experimental models to mixed cognitive outcomes in clinical trials, emerging evidence is testing whether GLP-1 receptor agonists can move beyond metabolic therapy to become meaningful treatments for Alzheimer’s disease.

GLP-1 Receptor Agonists in Migraine and Intracranial Hypertension: Emerging Off-Label Therapeutic Potential

https://www.news-medical.net/health/GLP-1-Receptor-Agonists-in-Migraine-and-Intracranial-Hypertension-Emerging-Off-Label-Therapeutic-Potential.aspx GLP-1 receptor agonists are emerging as promising investigational therapies for idiopathic intracranial hypertension, with evidence suggesting reductions in intracranial pressure, headache burden, papilledema, and visual complications. Their potential role in primary migraine remains far less certain and requires dedicated randomized clinical trials.

What 3,600 adults with diabetes revealed about lifestyle and heart health

https://www.news-medical.net/news/20260819/What-3600-adults-with-diabetes-revealed-about-lifestyle-and-heart-health.aspx A UK Biobank analysis followed more than 3,600 adults with type 2 diabetes to examine how diet, sleep, physical activity, and social habits relate to major cardiovascular events and survival. In a recent study published in the journal eClinicalMedicine, researchers investigated associations between adherence to a Mediterranean lifestyle and the risk of major adverse cardiovascular events (MACE) and mortality in adults with type 2 diabetes (T2D).

Recent Discoveries About Latent Obstruction in Hypertrophic Cardiomyopathy Authors: Mark V. Sherrid, MD

https://www.medscape.org/viewarticle/recent-discoveries-about-latent-obstruction-hypertrophic-2026a1000rwy?page=1

No Overall Increased Risk of Death in Individuals With Sickle Cell Trait: A Study of 467 779 General Population Adults Authors: Marie Warny, MD, PhD; Andreas Glenthøj, MD, PhD; Shoaib Afzal, MD, PhD, DMSc; Shaodong Wei, PhD; Jesper Petersen, PhD; Jens Helby

https://www.medscape.org/viewarticle/no-overall-increased-risk-death-individuals-sickle-cell-2026a1000rs9?page=1

Risk Assessment of Thyroid Nodules: A Practical Guide Mauricio Wajngarten

https://www.medscape.com/viewarticle/risk-assessment-thyroid-nodules-practical-guide-2026a1000s5k?src=

Active Surveillance Rises as Focal Therapy Persists in Prostate Cancer Frederik Joelving

https://www.medscape.com/viewarticle/active-surveillance-rises-focal-therapy-persists-prostate-2026a1000srp

Belgian Algorithm Reshapes Endometrial Cancer Care Isabelle Catala

https://www.medscape.com/viewarticle/belgian-algorithm-reshapes-endometrial-cancer-care-2026a1000spv?src=

Symptoms May Signal Clinically Significant Prostate Cancer in Primary Care Settings Edited by Manasi Talwadekar

https://www.medscape.com/viewarticle/symptoms-may-signal-clinically-significant-prostate-cancer-2026a1000s00?src=

Beyond the boardroom: how the Lions’ Den is redefining patient-industry dialogue at the International PBC Summit 2026 Written by Becky Pender, senior associate, RARE Revolution Magazine

https://rarerevolutionmagazine.com/beyond-the-boardroom-how-the-lions-den-is-redefining-patient-industry-dialogue-at-the-international-pbc-summit-2026/ The International PBC Summit has long been heralded as a crucial meeting point for all stakeholders invested in primary biliary cholangitis (PBC). Yet, year after year, it is the distinctive and often challenging Lions’ Den session that captures the greatest attention and drives the most profound outcomes. Taking place on day three of the summit, the Lions’ Den is not a passive forum or a polished presentation, but a direct, structured dialogue specifically designed to confront a central challenge in modern healthcare: the persistent lack of transparent and equal access for patients and advocates to the pharmaceutical companies developing their treatments. The Summit saw approximately 20 patient advocacy groups (PAGs) attend, with four pharmaceutical companies participating in the session. This one-to-many relationship creates a uniquely controlled and transparent environment for engagement. The structure itself is simple yet highly effective: a company presents its work, insights or pipeline, followed immediately by a dedicated Q&A session where PAGs lead the questioning on topics ranging from new treatments and clinical trial design to the often-thorny issue of access to therapies. The rotation ensures every participating company is engaged one at a time, guaranteeing all PAGs participate in each interaction, thereby ensuring equity in access to knowledge. The anatomy of trust and accountability The core value of the Lions’ Den format lies in its capacity to create a rare space where PAGs can engage with industry as equal stakeholders. This standardisation is crucial for levelling the playing field. By ensuring that every company receives the same amount of time, the same format and is subjected to the same type of questioning, the mechanism reduces the inherent power imbalance that frequently exists between large, well-resourced pharmaceutical companies and smaller patient organisations with limited experience in high-stakes negotiations. In this environment, PAGs are freed from the necessity to ‘perform diplomacy’ constantly. Instead, the format encourages genuine openness and accountability while maintaining respect. As one patient advocate described, this structure provides a necessary safety net: “For smaller organisations especially, standardisation creates safety. It gives everyone the same opportunity to participate and ensures that the patient perspective is not overshadowed by influence, size or funding capacity.” – patient advocate The discussions that emerge are often far more direct and practical than those in traditional settings, covering difficult questions about access, timelines, affordability, communication and unmet needs, which might otherwise be glossed over in overly polished or general meetings. “The core value is creating a rare space where patient advocacy groups can speak openly and directly with industry as equal stakeholders. The format fosters honesty and accountability.” – PAG member

A single viral platform shows promise across infectious disease and cancer ReiThera’s gorilla-derived adenovirus vector is helping advance vaccines and therapies for COVID-19, HIV, Ebola, and even cancer. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/a-single-viral-platform-shows-promise-across-infectious-disease-and-cancer-17103?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-9AVNke2GsjfUAH4klAHUbDwd9KUHvUb7XOLqpTqqD969vkKpbA_anyAowbUKoDN2KhFojXwlgJo1VRt3JP_tvUWDypmA&_hsmi=433938578&utm_content=433938578&utm_source=hs_email At Advanced Therapies 2026, DDN spoke with Claudio Panzarella, Head of Business Development, and Angelo Raggioli, Head of Technology Development, at ReiThera, about how the company’s early COVID-19 vaccine efforts shaped its current scientific programs, including the gorilla adenovirus (GRAd) platform, ongoing HIV vaccine trials, and the potential for oncology therapeutics.

Triple drug therapy could clear HIV in infected newborns Scientists showed that a trio of medications successfully cleared the virus in a rhesus macaque infant model. Clinical testing in human infants could move quickly. Written byAllison Whitten, PhD

https://www.drugdiscoverynews.com/triple-drug-therapy-could-clear-hiv-in-infected-newborns-17446 In 2013, a baby girl known as the “Mississippi baby” made headlines when it was announced that she was cured of HIV. She had received antiretroviral therapy (ART) starting just 30 hours of birth up until 18 months, and had no detectable levels of the virus over two years later. But then, when she was almost four years old, her blood revealed the HIV had returned, and she had to start ART once again.

Endocrine Disorders

Endocrine Disorders According to the NIH, there are more than 175 rare diseases that affect the endocrine system. In this section we highlight many of them and provide clinically relevant perspectives on these rare diseases. https://checkrare.com/diseases/endocrine-disorders/

Congenital And Genetic Conditions

https://checkrare.com/diseases/congenital-and-genetic-conditions/ Congenital and genetic conditions can be inherited or caused by environmental factors and can vary from mild to severe. This section is focused on genetic and congenital disorders in children and adolescents.

Autoimmune / Autoinflammatory Disorders

https://checkrare.com/diseases/autoimmune-autoinflammatory-disorders/ Disease overviews, clinically relevant perspectives, and news about the most important research in rare autoimmune and auto-inflammatory disorders.

Importance of Patient Listening in The Development of Rare Disease Treatments by Madaline Spencer| Published on: Aug 19, 2026

Importance of Patient Listening in The Development of Rare Disease Treatments by Madaline Spencer| Published on: Aug 19, 2026 Matt Trudeau, President of ITF Therapeutics, discusses the importance of patient listening in the development of Duvyzat (givinostat) for Duchenne muscular dystrophy (DMD). https://checkrare.com/importance-of-patient-listening-in-the-development-of-rare-disease-treatments/

Navigating Advances in TRK Fusion-Positive Cancers: A Collaborative Journey From Testing to Therapy Authors: David S. Hong, MD; Theodore W. Laetsch, MD; Jonathan C. Trent, MD, PhD

https://www.medscape.org/viewarticle/navigating-advances-trk-fusion-positive-cancers-2025a1000z5i?page=1&src=mkmcmr_driv_stan_mscpedu_260817-OUS-HONC-navigating-advances-trk-fusion-positive-cancers-2025a1000z5i-cta&uac=148436CN

Navigating the HER2 Spectrum in Breast Cancer: Evolving Diagnostic Paradigms for Clinical Excellence Authors: Sara M. Tolaney, MD, MPH; Frédérique Penault-Llorca, MD; Giuseppe Curigliano, MD, PhD

https://www.medscape.org/viewarticle/navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea?page=1&src=mkmcmr_driv_stan_mscpedu_260818-OUS-HONC-navigating-her2-spectrum-breast-cancer-evolving-diagnostic-2026a10004ea-cta&uac=148436CN

NOACs Linked to Slower Cognitive Decline in Comorbid AF and Alzheimer’s Disease Lizette Borreli

https://www.medscape.com/viewarticle/noacs-linked-slower-cognitive-decline-comorbid-af-and-2026a1000smf?ecd=WNL_trdalrt_pos1_ous_260819_etid8610903&uac=148436CN&impID=8610903 Non-vitamin K oral anticoagulant (NOAC) use was associated with modestly slower cognitive decline among older adults with comorbid atrial fibrillation (AF) and Alzheimer’s disease (AD).

Tenosynovial Giant Cell Tumor in Focus: Quickfire Insights From Multidisciplinary Experts Authors: Hans Gelderblom, MD, PhD; Michiel van de Sande, MD, PhD

https://www.medscape.org/viewarticle/tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py?page=1&src=mkmcmr_driv_stan_mscpedu_260819-OUS-HONC-tenosynovial-giant-cell-tumor-focus-quickfire-insights-2026a10006py-cta&uac=148436CN

Myasthenia Gravis Clinical Research Highlights

https://checkrare.com/learning/p-myasthenia-gravis-clinical-research-highlights-2026/

Type 1 Plasminogen Deficiency Overview by Madaline Spencer| Published on: Mar 13, 2026 + + +

Type 1 Plasminogen Deficiency Overview by Madaline Spencer| Published on: Mar 13, 2026 Amy Shapiro, MD, a pediatric hematologist and the Medical Director and CEO of the Indiana Hemophilia and Thrombosis Center in Indianapolis, provides CheckRare an overview on type 1 plasminogen deficiency (PLGD-1). https://checkrare.com/type-1-plasminogen-deficiency-overview/ Diagnosis and Management of Plasminogen Deficiency by Madaline Spencer| Published on: May 11, 2026 Amol Sura, MD, Foster Center for Ocular Immunology, Dept of Ophthalmology, Duke University, Durham, North Carolina, discusses the diagnosis and management of plasminogen deficiency, a rare condition in which the eyes are first affected, but it manifests in mucous membranes throughout the body. https://checkrare.com/diagnosis-and-management-of-plasminogen-deficiency/ Key Features of PLGD-1 by Madaline Spencer| Published on: May 19, 2026 Angela Zhu, MD, is an Ophthalmologist and Clinical Assistant Professor, Pediatric & Adult Cornea/Cataract/External Diseases, at Bascom Palmer Eye Institute in Miami. In this interview with CheckRare, Dr. Zhu describes some of the key features of plasminogen deficiency and why ophthalmologists are often the healthcare providers who begin the process toward diagnosis. https://checkrare.com/diagnosis-and-management-of-plasminogen-deficiency-2/

Plasminogen Deficiency: Fibrin Accumulation and Its Effects on Patients by CheckRare Staff| Updated on: Jul 16, 2026

https://checkrare.com/plasminogen-deficiency-fibrin-accumulation-and-its-effects-on-patients-2/

FDA Approves Iberdomide Combination Therapy for Relapsed/Refractory Multiple Myeloma by Madaline Spencer| Published on: Aug 18, 2026

https://checkrare.com/fda-approves-iberdomide-combination-therapy-for-relapsed-refractory-multiple-myeloma/

Rare Endocrine Exchange: Why This Conversation Matters by CheckRare Staff| Published on: Aug 18, 2026

https://checkrare.com/rare-endocrine-exchange-why-this-conversation-matters/

Solar Geoengineering: Climate Cure or Health Gamble? Manuela Callari

https://www.medscape.com/viewarticle/solar-geoengineering-climate-cure-or-health-gamble-2026a1000skt

NPM1-Mutated AML: Not All Treatments Are Equal Edited by Katie Lennon

https://www.medscape.com/viewarticle/npm1-mutated-aml-not-all-treatments-are-equal-2026a1000sl8?src=

Glofitamab-GemOx Shows Sustained Survival Benefit in DLBCL Edited by Gargi Mukherjee

https://www.medscape.com/viewarticle/glofitamab-gemox-shows-sustained-survival-benefit-dlbcl-2026a1000sle?src=

20-Year Study Ties Nitrites to Colon Cancer, in Men Only Edited by Amy Norton

https://www.medscape.com/viewarticle/20-year-study-ties-nitrites-colon-cancer-men-only-2026a1000skv

The Future Directions Across the Spectrum of Breast Cancer Want to stay up to date on the optimal management approaches for your patients?

https://www.medscape.org/advances/pan-breast-cancer-2026a1000o7i?src=ban_driv_260303_mscpedu_447301.01_ace

Optimizing Breast MRI Surveillance in High-Risk Patients: Strategies for Repeat Imaging Excellence Authors: Katja Pinker-Domenig, MD, PhD; Ritse M. Mann, MD, PhD

https://www.medscape.org/viewarticle/optimizing-breast-mri-surveillance-high-risk-patients-2026a1000nau?page=1&src=mkmcmr_driv_32025_mscpedu_451838.25_ace_launch&uac=148436CN

A framework for mindfulness-based social-emotional learning in Vietnamese schools Phi-Bao Nguyen-Ngoc, Thien-Vu Giang, Van-Son Huynh Volume 3, Issue 3

https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav Adolescent mental health has become an increasing concern in Vietnam and Southeast Asia, where schools are expected to play a stronger role in wellbeing promotion. Although social-emotional learning (SEL) and mindfulness-based approaches have both shown promise in promoting students’ psychological wellbeing, their integration in Vietnamese schools remains underdeveloped. This paper proposes a framework for mindfulness-based social-emotional learning (MBSEL) in Vietnamese schools. A narrative review was conducted through searches of Scopus, Web of Science, ERIC, PsycINFO, and Google Scholar, supplemented by reference-list screening, to identify English-language conceptual, empirical, and policy literature on SEL, mindfulness, adolescent development, school mental health, and culturally responsive education published up to June 2026. The literature was critically synthesized to examine conceptual connections, intervention evidence, and implications for Vietnam. The synthesis indicates that mindfulness and SEL are complementary. Existing MBSEL-related programs provide encouraging but uneven evidence, with stronger support for stress reduction, emotion regulation, and self-compassion than for interpersonal and school-climate outcomes. The proposed framework positions mindfulness as a facilitating mechanism supporting SEL competencies among students, teachers, and other school stakeholders, thereby contributing to safer, more caring, and respectful environments aligned with Vietnam’s Happy School initiatives. As a narrative review without formal quality or risk-of-bias appraisal, the synthesis may be affected by selection and language bias and does not support definitive causal conclusions. MBSEL should therefore be implemented through cultural adaptation, teacher preparation, whole-school support, and rigorous empirical evaluation. https://www.academia.edu/2997-9196/3/3/10.20935/MHealthWellB8427

Managing Myeloproliferative Neoplasms: Practice Your Skills in These Virtual Patient Simulations Authors: Claire N. Harrison, DM, FRCP, FRCPath; Haifa Kathrin Al-Ali, MD

https://www.medscape.org/viewarticle/managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o?page=1&src=mkmcmr_driv_psims_mscpedu_260817-OUS-HONC-managing-myeloproliferative-neoplasms-practice-your-skills-2026a1000f5o-cta&uac=148436CN

Ca10H Linked to Improved Colorectal Cancer Outcomes Álvaro de la Serna

https://www.medscape.com/viewarticle/translate-un-biomarcador-at%C3%ADpico-apunta-un-mejor-2026a1000s3j?ecd=WNL_trdalrt_pos1_ous_260818_etid8607326&uac=148436CN&impID=8607326

Shaping the Future of Precision Oncology: Biomarker-Driven Care for Tumor-Agnostic Therapies Authors: Benedikt Westphalen, MD, PhD; Vivek Subbiah, MD

https://www.medscape.org/viewarticle/shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk?page=1&src=mkmcmr_driv_stan_mscpedu_260818-OUS-HONC-shaping-future-precision-oncology-biomarker-driven-care-2026a1000jpk-cta&uac=148436CN

Can AI uncover a new path to non-opioid pain relief? As non-opioid pain therapies continue to face setbacks, Insilico is using AI to uncover new biology and therapeutic targets. Written byBree Foster, PhD

Can AI uncover a new path to non-opioid pain relief? As non-opioid pain therapies continue to face setbacks, Insilico is using AI to uncover new biology and therapeutic targets. Written byBree Foster, PhD https://www.drugdiscoverynews.com/can-ai-uncover-a-new-path-to-non-opioid-pain-relief-17425 The search for effective non-opioid pain medicines has produced both breakthroughs and setbacks. While the approval of Vertex Pharmaceuticals’ non-opioid drug Journavx in 2025 offered a new option for acute pain, it didn’t see the immediate commercial success many analysts anticipated, with third-quarter sales falling $3 million short of expectations. This was quickly followed by Vertex then discontinuing a follow-up non-opioid candidate after disappointing clinical results. Meanwhile, Eli Lilly has shelved two non-opioid drug candidates.

Parkinson’s patient’s yearslong tremor vanishes within minutes of new ultrasound treatment +...

https://www.foxnews.com/health

Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study Axel Svedbom, PhDa,b Send email to axel.svedbom@ki.se ∙ Lotus Mallbris, MDa,c ∙ Alen Zabotti, MDd ∙ Martin P Playford, PhDe ∙ Pernilla Nikamo, PhDa ∙ Nehal N Mehta, MDf ∙ et al.

Predicting psoriatic arthritis in new-onset psoriasis: development of multivariable prediction models from an inception cohort study Axel Svedbom, PhDa,b Send email to axel.svedbom@ki.se ∙ Lotus Mallbris, MDa,c ∙ Alen Zabotti, MDd ∙ Martin P Playford, PhDe ∙ Pernilla Nikamo, PhDa ∙ Nehal N Mehta, MDf ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00115-3/abstract?dgcid=raven_jbs_etoc_feature_lanrhe

Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY Mark D Russell, PhDa Send email to mark.russell@kcl.ac.uk ∙ Andrea Schaffer, PhDc ∙ Zijing Yang, PhDa ∙ Arti Mahto, PhDd ∙ Katie Bechman, PhDa ∙ Chris Wincup, PhDd ∙ et al.

Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY Mark D Russell, PhDa Send email to mark.russell@kcl.ac.uk ∙ Andrea Schaffer, PhDc ∙ Zijing Yang, PhDa ∙ Arti Mahto, PhDd ∙ Katie Bechman, PhDa ∙ Chris Wincup, PhDd ∙ et al. https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00142-6/fulltext?dgcid=raven_jbs_etoc_feature_lanrhe

Translating progress into patient benefit in dermatomyositis The Lancet Rheumatology +...

Translating progress into patient benefit in dermatomyositis The Lancet Rheumatology https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(26)00256-0/fulltext?dgcid=raven_jbs_etoc_email Sep 2026 Volume 8Number 9e675-e756 https://www.thelancet.com/journals/lanrhe/issue/vol8no9/PIIS2665-9913(26)X2008-2

Semaglutide Use and Risk for Depression Show No Clear Association

https://www.medscape.com/viewarticle/semaglutide-use-and-risk-depression-show-no-clear-2026a1000s4u?src= The use of semaglutide was not associated with an increased risk for depression compared with placebo or other antidiabetic/antiobesity agents, but the evidence was limited and of very low certainty.

Cannabis Use May Increase Fall Risk in Adults With HIV

https://www.medscape.com/viewarticle/cannabis-use-may-increase-fall-risk-adults-hiv-2026a1000s50?src= Cannabis use in the past month was associated with a higher risk for falls among adults living with HIV. However, after adjusting for other substance use, prescribed medications, and comorbidities, the association was no longer statistically significant.

Adrenal Incidentalomas: When to Worry and What to Test F. Watto, MD; Paul N. Williams, MD

https://www.medscape.com/viewarticle/adrenal-incidentalomas-when-worry-and-what-test-2026a1000r3r?src=

Understanding the 'Wait Time Paradox' in Ovarian Cancer Dr Maurie Markman

https://www.medscape.com/viewarticle/understanding-wait-time-paradox-ovarian-cancer-2026a1000puk?src=

Fact or Fiction: Multiple Sclerosis Diagnosis and Workup Reviewed by Christopher C. Luzzio, MD

https://reference.medscape.com/viewarticle/fact-or-fiction-multiple-sclerosis-diagnosis-and-workup-2026a1000nsr?src=&_gl=1*667rps*_gcl_aw*R0NMLjE3ODM4NzAxMzguQ2p3S0NBanc5c3pTQmhCTkVpd0FDNTdTcTJZUXZTZkkxc01raEZQZ1VLSWRQZkVUdGU4U212WEI0NGh3aEE5WmMtVDhTSVBEWlBzNmdSb0NiT1FRQXZEX0J3RQ..*_gcl_au*NjkzMDY5MjIxLjE3ODA2NzA2MDAuMTY4MzI1MDM3LjE3ODY5NzI2OTIuMTc4Njk3NDg1Mi4yMTI0OTM5ODg4LjE3ODY4OTIyNTQuMTc4Njk3NDg1Mg.. The 2024 revision of the McDonald criteria has substantially refined how clinicians diagnose multiple sclerosis (MS), placing greater emphasis on robust imaging and cerebrospinal fluid (CSF)-based evidence. The updated framework incorporates new MRI biomarkers, revised CSF parameters, and tailored guidance for specific patient subgroups, such as individuals with radiologically isolated syndrome (RIS) and older adults.

Mastectomy Preserves Ventriculoperitoneal Shunt in Woman

https://www.medscape.com/viewarticle/mastectomy-preserves-ventriculoperitoneal-shunt-woman-2026a1000s45?src= Preserving a ventriculoperitoneal (VP) shunt during breast cancer surgery may be feasible when the tumor is close to the catheter and shunt dependence precludes removal. This case demonstrated that careful preoperative imaging, multidisciplinary planning, avoidance of energy devices near the catheter, and meticulous sharp dissection allowed the shunt to be preserved during mastectomy without damage or subsequent complications.

Fast Five Quiz: Psoriasis and Pregnancy Reviewed by Shari Lipner, MD, PhD

https://reference.medscape.com/viewarticle/psoriasis-and-pregnancy-2026a1000oia?src=&_gl=1*o84t4p*_gcl_aw*R0NMLjE3ODM4NzAxMzguQ2p3S0NBanc5c3pTQmhCTkVpd0FDNTdTcTJZUXZTZkkxc01raEZQZ1VLSWRQZkVUdGU4U212WEI0NGh3aEE5WmMtVDhTSVBEWlBzNmdSb0NiT1FRQXZEX0J3RQ..*_gcl_au*NjkzMDY5MjIxLjE3ODA2NzA2MDAuMTY4MzI1MDM3LjE3ODY5NzI2OTIuMTc4Njk3NDg1Mi4yMTI0OTM5ODg4LjE3ODY4OTIyNTQuMTc4Njk3NDg1Mg.. Because psoriasis can affect female patients during their reproductive years, pregnancy commonly overlaps with ongoing disease management. Clinical care during pregnancy focuses on balancing maternal disease control with fetal safety using evidence-based treatment decisions and including multidisciplinary input when needed.

Switching to Integrase Inhibitors Does Not Raise Long-Term Heart Disease Risk in People With HIV +++ +++ +

Integrase Inhibitors Safe for Heart in HIV Patients Switching to Integrase Inhibitors Does Not Raise Long-Term Heart Disease Risk in People With HIV Medscape Medical News 57 minutes ago https://www.medscape.com/viewarticle/switching-integrase-inhibitors-does-not-raise-long-term-2026a1000s47?src= One Third of Patients Achieve Clinically Meaningful Weight Loss With Dietitian-Led Primary Care Treatment Early Dietitian Visits Linked to Successful Weight Loss Medscape Medical News 1 hour ago https://www.medscape.com/viewarticle/one-third-patients-achieve-clinically-meaningful-weight-loss-2026a1000s11?src= Diabetes Drug Curbs Weight Gain in Older People With HIV Diabetes Drug Curbs Weight Gain in Older People With HIV Medscape News UK 2 hours ago https://www.medscape.com/viewarticle/diabetes-drug-curbs-weight-gain-older-people-hiv-2026a1000rq9?src= Obesity Class III Linked to Death Risk in Younger Adults Medscape Medical News 55 minutes ago https://www.medscape.com/viewarticle/obesity-class-iii-linked-increased-mortality-risk-younger-2026a1000s44?src= Gram-Negative Bacteria Lead Pediatric Cancer BSIs Medscape Medical News 1 hour ago https://www.medscape.com/viewarticle/gram-negative-bacteria-dominate-bloodstream-infections-2026a1000s3s?src= SLE Linked to Increased Risk for Venous Thromboembolism Medscape News UK 2 hours ago https://www.medscape.com/viewarticle/systemic-lupus-erythematosus-linked-increased-risk-venous-2026a1000ro9?src= Cigars, Pipes Up Lung Cancer Risk, Raise Screening Needs Medscape News UK 2 hours ago https://www.medscape.com/viewarticle/cigar-and-pipe-smoking-increases-risk-lung-cancer-and-2026a1000rqr?src=

Vagal Nerve Stimulation for Rheumatoid Arthritis a Year After Approval: Where Do Things Stand? Richard Mark Kirkner

https://www.medscape.com/viewarticle/vagal-nerve-stimulation-rheumatoid-arthritis-year-after-2026a1000s3y?src= Rheumatologist Ann Igoe, MD, has lived with debilitating rheumatoid arthritis (RA) since she was a 10-year-old girl in Ireland, but since she received a vagus nerve neuroimmune modulation implant in July that’s specifically indicated to treat RA, she said, “I actually felt like I won the lotto.”

Obesity Class III Linked to Increased Mortality Risk in Younger Adults August 17, 2026

https://www.medscape.com/viewarticle/obesity-class-iii-linked-increased-mortality-risk-younger-2026a1000s44?src=

RARE Revolution RARE Bite

https://editions.rarerevolutionmagazine.com/html5/reader/production/default.aspx?pubname=&edid=e0508b93-1cde-4785-b9ae-c36724bde55a&pnum=64 The International PBC Summit 2026, held from 20 to 23 April in Edinburgh, Scotland, by the PBC Foundation, represented an important patient‑centric healthcare collaboration. Far from a traditional conference, the Summit agenda was built upon a dynamic priority‑setting framework. This approach ensured that the work undertaken emerged from the collective wisdom of patients, clinical professionals, industry representatives, and advocates.

Importance of Patient Listening in The Development of Rare Disease Treatments

FDA Approves New Narcolepsy Treatment | The CheckRare Brief

Rare Endocrine Exchange: Why This Conversation Matters

Topline Results from the MonumenTAL-6 Clinical Trial in Adults With Relapsed/Refractory Multiple Myeloma by Madaline Spencer| Published on: Aug 17, 2026

Topline Results from the MonumenTAL-6 Clinical Trial in Adults With Relapsed/Refractory Multiple Myeloma by Madaline Spencer| Published on: Aug 17, 2026 Ajay K. Nooka, MD, MPH, FACP, Director of the Myeloma Program at the Emory University School of Medicine, discusses topline results from the MonumenTAL-6 clinical trial testing Tecvayli (teclistamab) in adults with relapsed/refractory multiple myeloma (RRMM). https://checkrare.com/topline-results-from-the-monumental-6-clinical-trial-in-adults-with-relapsed-refractory-multiple-myeloma/

ICER: AstraZeneca hypertension drug is too expensive

https://icer.org/wp-content/uploads/2026/08/ICER_Hypertension_Draft-Report_For-Publication_081226.pdf?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9uBnMRLalPLEhRK8bGLnNh6vHmUJPv1ozrbjVIHDxZY509xx0hGug-_oVpDXqOQh2H05n6PmGwxz2gezp79gbhfrjOcg&_hsmi=433538757&utm_content=433538757&utm_source=hs_email ICER: AstraZeneca hypertension drug is too expensive AstraZeneca’s newly approved hypertension drug Baxfendy is too expensive to meet traditional cost-effectiveness thresholds, according to a draft report from drug pricing watchdog ICER. The group assessed Baxfendy at its $10,800 annual list price. The group reached the same conclusion for Mineralys Therapeutics’ experimental rival lorundrostat. ICER said the benefits of the two aldosterone synthase inhibitors are “promising but inconclusive” compared with cheap generic hypertension drugs. AstraZeneca countered that Baxfendy, the first new class of hypertension drugs in more than two decades, produced clinically meaningful blood pressure reductions in a Phase 3 trial and could help millions of patients whose hypertension remains uncontrolled on multiple medications. AstraZeneca estimates that Baxfendy’s peak sales potential could be $5 billion after it acquired its original developer, CinCor Pharma, for $1.3 billion in 2023.

Europe pulls Tavneos over trial integrity concerns

https://www.ema.europa.eu/en/documents/referral/tavneos-article-20-procedure-scientific-conclusions_en.pdf?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9a5A20SZYGd8M6Nb1b4vZ-d6og2aCZq4NTj6pOmmp0etKLMXS803RY8RHNly5-2SjlV8UU-VDYjFUI4D6TBJQkdxIVvg&_hsmi=433538757&utm_content=433538757&utm_source=hs_email Europe pulls Tavneos over trial integrity concerns European regulators last week formally revoked the marketing authorization for Tavneos, the vasculitis treatment developed by ChemoCentryx — a company acquired by Amgen for $4 billion. The EMA concluded that the pivotal trial supporting its approval was unreliable, and that the sponsor personnel behind a Phase 3 study for the drug accessed unblinded efficacy data. Regulatory documents show that the EMA’s Committee for Medicinal Products for Human Use said the drug initially failed to demonstrate superiority at 52 weeks — before researchers re-adjudicated nine patients. This shifted the result from being statistically insignificant to significant, ultimately paving the path for approval, the agency said. Last month, NEJM retracted a paper outlining the Tavneos results. https://www.reuters.com/legal/litigation/amgen-submits-new-data-challenge-fdas-proposal-withdraw-tavneos-2026-07-24/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-8vPlSbdrxD1TiXXCgdg4Yp48T04RiPySjC01HDXF0RBf3ufNTdE1nBymSTjz6cE7Gj3EJIRKMJRg0VkSAmJ557nEB4iA&_hsmi=433538757&utm_content=433538757&utm_source=hs_email Regulators said the modifications weren’t adequately disclosed and amounted to a serious breach of good clinical practice. The agency also cited reports of fatal liver injury and vanishing bile duct syndrome, concluding that Tavneos’ benefits could no longer be shown to outweigh its risks. Amgen disputes the decision. It’s making a similar case to the FDA after the agency asked the company in January to voluntarily withdraw Tavneos from the U.S. market. A few weeks ago, Amgen submitted real-world evidence and an independent reanalysis of the trial to regulators. https://www.appliedclinicaltrialsonline.com/view/nejm-retracts-tavneos-trial-fda-ema-amgen-drug-market?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9liArKFfWvFTUPZX0Jl2OcDna6h08jkGnx6JxuKmsl-5IXyPJWjSLaaUXwCeV7Sx63HTGMgQBOrmR1-fFLAtiQO58Y-Q&_hsmi=433538757&utm_content=433538757&utm_source=hs_email

Akeso and Summit’s ivonescimab extends survival in squamous cell lung cancer ‘Two drugs in one’ candidate, developed in China, is a highlight at ASCO By Matthew HerperMay 31, 2026 Senior Writer, Medicine, Editorial Director of Events

https://www.statnews.com/2026/05/31/squamous-cell-lung-cancer-akeso-summit-harmoni-asco-2026/?utm_campaign=the_readout&utm_medium=email&_hsenc=p2ANqtz-9K_QeHmBTKiVP-VqCNkg3lSQlYPnOs74cV2rwrywwYrO9ZGNyS4Oxqoxf1APcYC0OGii-i_NBEGoDs4-icjir8jQyqAg&_hsmi=433538757&utm_content=433538757&utm_source=hs_email Akeso and Summit's lung cancer drug shows worsening tumor-progression benefit Chinese regulators on Friday approved an expanded use of ivonescimab, the PD-1/VEGF-targeting antibody made by the Chinese drugmaker Akeso, for the treatment of newly diagnosed squamous non-small cell lung cancer. The new prescription label, however, included a negative surprise: updated study results data showing a worsening tumor-progression benefit than previously reported. The new disclosure is potentially bad news Summit Therapeutics, which is developing ivonescimab for the U.S. and European markets. In an updated analysis of a study called HARMONi-6, the combination of ivonescimab and chemotherapy reduced the risk of tumor progression by 28%, down from 40% when the study was presented in May at the ASCO annual meeting. The improvement in overall survival shown by the ivonescimab-chemotherapy regimen has not changed, although it may with more mature data follow-up. How this impacts Summit and its ongoing HARMONI-3 study of ivonescimab in the same squamous lung cancer patient population is uncertain. Last September, the company said patients in North America and Europe had seen their cancer return faster than those in China. As a result, an interim analysis of progression-free survival did not meet a prespecified endpoint. A final analysis is expected later this year.

Decision-Making for Managing Myelofibrosis-Related Cytopenias: What Is Best Practice? Authors: Paola Guglielmelli, MD, PhD

https://www.medscape.org/viewarticle/decision-making-managing-myelofibrosis-related-cytopenias-2026a1000ar2?page=1&src=mkmcmr_driv_stan_mscpedu_260816-OUS-HONC-decision-making-managing-myelofibrosis-related-cytopenias-2026a1000ar2-cta&uac=148436CN

How Low Does PSA Need to Go in Metastatic Prostate Cancer?

https://www.medscape.com/viewarticle/how-low-does-psa-need-go-metastatic-prostate-cancer-2026a1000rpa?ecd=WNL_trdalrt_pos1_ous_260817_etid8604317&uac=148436CN&impID=8604317 A real-world analysis suggests that achieving a prostate-specific antigen (PSA) level < 0.2 ng/mL within 9 months of starting androgen deprivation therapy (ADT)-based treatments was the PSA benchmark most consistently associated with improved overall survival in men with metastatic castration-sensitive prostate cancer. Achieving a PSA level < 0.2 ng/mL within 9 months of ADT initiation was associated with a significantly lower subsequent risk for death, while achieving 90% or greater PSA decline but not a PSA level < 0.2 ng/mL was not tied to improved overall survival.

Advances in X chromosome inactivation open therapeutic opportunities for X-linked genetic disorders

https://www.news-medical.net/news/20260803/Advances-in-X-chromosome-inactivation-open-therapeutic-opportunities-for-X-linked-genetic-disorders.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=rare_diseases_newsletter_10_august_2026 A new review explores how advances in understanding X chromosome inactivation (XCI) are creating potential therapeutic opportunities for a range of X-linked genetic disorders, including Rett syndrome, Fabry disease, Duchenne muscular dystrophy, hemophilia, and others. The article examines the molecular mechanisms that control X chromosome silencing, the impact of skewed XCI on disease severity, emerging methods to measure XCI patterns, and experimental approaches aimed at reactivating beneficial genes on the inactive X chromosome.

FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone

Ion channel TPC1 identified as key regulator of iron homeostasis

https://www.news-medical.net/news/20260806/Ion-channel-TPC1-identified-as-key-regulator-of-iron-homeostasis.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=pharmacy_and_pharmacology_newsletter_14_august_2026

Enhancing Clinical Understanding of Oral SERD-Based Therapies for Patients With ER-Positive/HER2-Negative MBC Authors: Nadia Harbeck, MD, PhD; Virginia Kaklamani, MD, DSc; Gregory Vidal, MD, PhD

https://www.medscape.org/viewarticle/enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46?page=1&src=mkmcmr_driv_stan_mscpedu_260816-OUS-HONC-enhancing-clinical-understanding-oral-serd-based-therapies-2026a1000a46-cta&uac=148436CN

Society for Pediatric Dermatology (SPD) 2026 Annual Meeting +...

https://www.medscape.com/c25/p14/society-pediatric-dermatology-spd-2026-annual-meeting-2026a1000mgj?ecd=wnl_conf_derm_SPD_NON-SPON_260811_mscpedit_conf1_etid8584150&uac=148436CN&impID=8584150

HMGCR emerges as a promising target for precision cancer therapies + + +

HMGCR emerges as a promising target for precision cancer therapies https://www.news-medical.net/news/20260805/HMGCR-emerges-as-a-promising-target-for-precision-cancer-therapies.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 HMGCR emerges as a promising target for precision cancer therapiesA growing body of evidence is reshaping how scientists and clinicians understand the role of cancer metabolism, placing the enzyme HMGCR at the center of a rapidly evolving therapeutic landscape. Tuft cell-like cancers exhibit unique biological characteristics across multiple organs https://www.news-medical.net/news/20260806/Tuft-cell-like-cancers-across-multiple-organs-exhibit-unique-biological-characteristics.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Tuft cell-like cancers exhibit unique biological characteristics across multiple organsA growing body of evidence suggests that a rare epithelial cell type known as the tuft cell may play a far more significant role in cancer than previously recognized. Early radionuclide therapy delays progression in metastatic prostate cancer https://www.news-medical.net/news/20260806/Early-radionuclide-therapy-delays-progression-in-metastatic-prostate-cancer.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

Ferroptosis-based therapy shows promise for advanced prostate cancer treatment + + + + +

https://www.news-medical.net/news/20260806/Ferroptosis-based-therapy-shows-promise-for-advanced-prostate-cancer-treatment.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC). The authors synthesize current knowledge of ferroptosis mechanisms, biomarkers, therapeutic agents, combination strategies, and translational challenges, proposing a framework that links ferroptosis regulatory networks with precision medicine approaches. Tadalafil may increase glaucoma risk in men with enlarged prostates https://www.news-medical.net/news/20260804/Tadalafil-may-increase-glaucoma-risk-in-men-with-enlarged-prostates.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 An erectile dysfunction drug that is also used to treat symptoms like sudden urgency and frequency, which are associated with an enlarged prostate in men, may heighten the risk of the serious eye condition, glaucoma, finds a large comparative study published online in the British Journal of Ophthalmology. Older men’s sexual priorities extend well beyond erectile function https://www.news-medical.net/news/20260806/Older-mene28099s-sexual-priorities-extend-well-beyond-erectile-function.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 A web-based survey of 6,000 Japanese men aged 50 or older found that sexual arousal was the function they most wanted to preserve, while erection became more highly valued as erectile function worsened. Erection showed the earliest age-related decline pattern, whereas ejaculation was the function most often reported as lost in older age. AI tool helps customize radiopharmaceutical therapy dosingAI tool helps customize radiopharmaceutical therapy dosing https://www.news-medical.net/news/20260804/AI-tool-helps-customize-radiopharmaceutical-therapy-dosing.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Radiopharmaceutical therapy (RPT) has made great strides over the last 50 years, having only recently received FDA approval to treat prostate cancer. But despite the progress-and billions of dollars of industry investments-one area that has lagged behind is dosing, which is still one-size-fits-all. Study identifies a novel direct drug target for head and neck squamous cell carcinomaStudy identifies a novel direct drug target for head and neck squamous cell carcinoma https://www.news-medical.net/news/20260806/Study-identifies-a-novel-direct-drug-target-for-head-and-neck-squamous-cell-carcinoma.aspx?utm_source=news_medical_newsletter&utm_medium=email&utm_campaign=prostate_cancer_newsletter_10_august_2026 Chemotherapy remains a cornerstone of treatment for head and neck cancers, the seventh-most common cancer type worldwide.

Blocking caspase-1 appears to reduce the risk of developing lung tumors

https://www.news-medical.net/news/20260814/Blocking-caspase-1-appears-to-reduce-the-risk-of-developing-lung-tumors.aspx Every year, lung cancer kills more than 100,000 people in the United States. Smoking is the leading risk factor for lung cancer, but other environmental exposures can also contribute to the disease. In an advance that could help prevent some of those lung cancer deaths, MIT researchers have shown that blocking an enzyme involved in lung inflammation appears to reduce the risk of developing tumors.

Saliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study Jennifer Serwanga, PhDa,b,c Send email to jennifer.serwanga@mrcuganda.org ∙ Raymond Ernest Kaweesa, MBChBa ∙ Deborah Mukisa, BSca,b ∙ Geoffrey Odoch, BSca,b ∙ Brenda Nairuba, MBChBd ∙ Violet Ankunda, MScb ∙ et al.

Saliva versus lesion swabs for PCR diagnosis of acute-phase clade Ib mpox in Uganda: a prospective matched hospital cohort study Jennifer Serwanga, PhDa,b,c Send email to jennifer.serwanga@mrcuganda.org ∙ Raymond Ernest Kaweesa, MBChBa ∙ Deborah Mukisa, BSca,b ∙ Geoffrey Odoch, BSca,b ∙ Brenda Nairuba, MBChBd ∙ Violet Ankunda, MScb ∙ et al. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00050-9/fulltext?dgcid=raven_jbs_etoc_feature_lanmic

Widespread circulation of Alongshan virus in Austria and serological evidence for infection in humans: a nationwide molecular and serological observational study David M Florian, MDa ∙ Paul Jetzingera ∙ Anna-Margarita Schöttab ∙ Iris Medits-Weiss, PhDa ∙ Moritz Irgang, DVMc ∙ Cara L Ebert, PhDd,e ∙ et al.

Widespread circulation of Alongshan virus in Austria and serological evidence for infection in humans: a nationwide molecular and serological observational study David M Florian, MDa ∙ Paul Jetzingera ∙ Anna-Margarita Schöttab ∙ Iris Medits-Weiss, PhDa ∙ Moritz Irgang, DVMc ∙ Cara L Ebert, PhDd,e ∙ et al. https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(26)00059-5/fulltext?dgcid=raven_jbs_etoc_feature_lanmic

The human gut microbiome: still more questions than answers The Lancet Microbe +...

The human gut microbiome: still more questions than answers The Lancet Microbe https://www.thelancet.com/journals/lanmic/issue/vol7no8/PIIS2666-5247(26)X2007-9

Building Care Plans With Radiopharmaceuticals for Patients With mCRPC Authors: Neal D. Shore, MD, FACS; Alicia Morgans, MD, MPH, FASCO; Chad Tang, MD

https://www.medscape.org/viewarticle/building-care-plans-radiopharmaceuticals-patients-mcrpc-2026a10007zy?page=1&src=mkmcmr_driv_stan_mscpedu_260811-OUS-HONC-building-care-plans-radiopharmaceuticals-patients-mcrpc-2026a10007zy-cta&uac=148436CN

Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial

Human versus analogue insulin for children and young adults with type 1 diabetes in low-resource settings (HumAn-1): a multicentre, open-label, randomised controlled trial Dr Jing Luo, MDa Send email to luoj@pitt.edu ∙ Sylvia Kehlenbrink, MDb ∙ Chung-Chou H Chang, PhDa,c ∙ Christina M Lalama, MSa ∙ Jill Kirsch, MSa ∙ Éimhín Ansbro, MDd ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00097-5/abstract?dgcid=raven_jbs_etoc_feature_landia

Whole-population trends in obesity across dimensions of inequality in England, 2019–25: a retrospective, longitudinal cohort study of 54 million adults

Whole-population trends in obesity across dimensions of inequality in England, 2019–25: a retrospective, longitudinal cohort study of 54 million adults Robert A Fletcher, MSca,b,d,f Send email to raf69@medschl.cam.ac.uk ∙ Nathalie Conrad, DPhilg,h ∙ Patrick Rockenschaub, PhDi ∙ Stelios Boulitsakis Logothetis, MEnga,b ∙ Brendon L Neuen, PhDf,j ∙ Fionna Chalmers, MSce ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(26)00120-8/fulltext?dgcid=raven_jbs_etoc_feature_landia

Soaring GLP-1 receptor agonist use The Lancet Diabetes & Endocrinology +...

Soaring GLP-1 receptor agonist use The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/issue/vol14no9/PIIS2213-8587(26)X2007-1

Most Read Cancer Science & Oncogenesis (+...)

https://read.qxmd.com/collection/1133?ecd=wnl_readmost_260814

Blended mobile health and wellness coaching enhances student engagement in mental health care Michael Reifman [1] , Xiao Cao [1] , Michelle L. Rozwadowski [1] , Jaeryeong Kim [1] , Maxwell Kluge [1] , Uma L. Subrayan [1] , Marsha Benz [2] , Amanda Reis [2] , Jevon Moore [2] , Kerby Shedden [3] , Sung Won Choi* [1]

https://www.academia.edu/2997-9196/3/2/10.20935/MHealthWellB8298 Introduction: Mental health challenges are common among college students, highlighting the need for scalable approaches that aim to reduce distress and support well-being. mHealth tools may complement campus services, though sustained engagement may be difficult. This study sought to discover how a blended intervention combining an mHealth positive psychology intervention (PPI) app with optional wellness coaching might impact student well-being. Materials and methods: In this single-arm pilot study, 28 students at a public university were given access to a PPI app (Roadmap 2.0) with mood tracking, a Fitbit® wearable device, and optional wellness coaching. Data sources included PROMIS® surveys at baseline and monthly follow-ups, daily mood ratings, app engagement logs, wearable-derived activity metrics, coaching attendance, and optional exit interviews. Analyses were descriptive and exploratory. Results: From baseline to exit, participants showed descriptive increases in PROMIS® global mental health and positive affect and decreases in depression, anxiety, fatigue, and anger. App engagement declined over time. In exploratory models, app engagement was lower among participants reporting greater psychosocial resources or support. Mood ratings were higher in the days following PPI activity completion, and PPI activity users were observed to have higher mood ratings over time. Interviews supported perceived app–coaching synergy and identified barriers to sustained engagement. Conclusions: A blended PPI mHealth app plus wellness coaching appears feasible in a real-world college setting and was associated with favorable descriptive trends in mental health and well-being outcomes. Controlled studies are needed to evaluate efficacy and assess app versus coaching contributions. https://www.academia.edu/journals/academia-mental-health-and-well-being/articles?source=journal-top-nav

Dissecting the Evidence: Interpreting Recent Clinical Trial Data for Radiopharmaceutical-Based Combinations in Metastatic Castration-Resistant Prostate Cancer Authors: Bertrand Tombal, MD, PhD; Alicia K. Morgans, MD, MPH, FASCO

https://www.medscape.org/viewarticle/dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un?page=1&src=mkmcmr_driv_stan_mscpedu_260815-OUS-HONC-dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un-cta&uac=148436CN

Clinical Perspectives on the Use of PI3K/AKT Pathway Inhibitors in the Management of HR+/HER2− Metastatic Breast Cancer Authors: Peter Schmid, MD, PhD, FRCP; Kevin Kalinsky, MD, MS, FASCO; Frédérique Penault-Llorca, MD, PhD

https://www.medscape.org/viewarticle/clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h?page=1&sso=true&src=mkmcmr_driv_stan_mscpedu_260816-OUS-HONC-clinical-perspectives-use-pi3k-akt-pathway-inhibitors-2026a100087h-cta&uac=148436CN

'Tony' Review: Anthony Bourdain's coming-of-age story unfolds in charming dramedy (+...)

'Tony' Review: Anthony Bourdain's coming-of-age story unfolds in charming dramedy Fox News Digital reviews A24's Anthony Bourdain coming-of-age dramedy "Tony" starring Dominic Sessa, Emilia Jones, Leo Woodall and Antonio Banderas. Directed by Matt Johnson. https://www.foxnews.com/lifestyle?lid=4u0xwkbm36dv

A Body at War: New Immune Reset By Ivanhoe Broadcast News on August 13, 2026Family

DENVER, Colo. (Ivanhoe Newswire) — More than 50 million Americans live with autoimmune diseases — conditions in which the immune system mistakenly attacks the body it’s supposed to protect. For many, treatment can mean years of medications to quiet that attack. But now, doctors are testing something far more aggressive: ways to reset or even replace the immune system itself. https://www.ivanhoe.com/family-health/a-body-at-war-new-immune-reset/

The Age Test: The 60 Second At-Home Check By Ivanhoe Broadcast News on August 17, 2026

Orlando, Fla. (Ivanhoe Newswire) — By 2030, the World Health Organization says one in six people on earth will be 60 or older. But here’s the good news: scientists say you can actually measure, in under a minute, whether you’re aging well or headed for trouble https://www.ivanhoe.com/?p=37451&preview=1&_ppp=3083c766b9

Retail Therapy Regret By Ivanhoe Broadcast News on August 18, 2026

Orlando, Fla. (Ivanhoe Newswire) — Americans are shopping around the clock and sometimes not for the reasons they think. From stress spending to “treat yourself” splurges, psychologists say buying something new can deliver a quick emotional lift but if it becomes your go-to way to cope with stress, boredom, or loneliness, it can start to damage more than your bank account. https://www.ivanhoe.com/?p=37454&preview=1&_ppp=c87d05b2f2

The Comfort Crisis By Ivanhoe Broadcast News on August 20, 2026

Orlando, Fla. (Ivanhoe Newswire) — Dinner delivered to your door. GPS for every turn. AI for every question. Modern life is built to make things faster, easier, and more convenient. But some experts say all that comfort may come with a cost, less patience, less focus, and less tolerance for discomfort, boredom, or effort. https://www.ivanhoe.com/?p=37460&preview=1&_ppp=199bbab0d2

Dynamic Pricing: The Price Jump Problem By Ivanhoe Broadcast News on August 19, 2026

Orlando, Fla. (Ivanhoe Newswire) — You’ve seen it with airfares, concert tickets, and rideshares. Prices that change by the hour, or even the minute. But consumer watchdogs say some companies may be going a step further, using personal data like your location, browsing history, and shopping habits to help decide what price or offer you see. The federal trade commission is now studying so-called “surveillance pricing.” https://www.ivanhoe.com/?p=37457&preview=1&_ppp=129314072e

Pesticide Problem: How To Reduce Your Exposure By Ivanhoe Broadcast News on August 21, 2026

Orlando, Fla. (Ivanhoe Newswire) — Pesticides are designed to kill pests but they can also end up in the places we live, breathe, and eat. Short-term exposure can irritate the eyes, skin, or throat, while some pesticides have also been linked to longer-term health concerns. And it’s not just about what’s on your produce. https://www.ivanhoe.com/?p=37463&preview=1&_ppp=37f04139fd

Würzburg researchers discover alternative approach to preventing thrombosis

https://www.news-medical.net/news/20260814/Wurzburg-researchers-discover-alternative-approach-to-preventing-thrombosis.aspx Glycoprotein VI, or GPVI for short, is a surface receptor found exclusively on platelets and their precursor cells, megakaryocytes in the bone marrow. GPVI is primarily responsible for binding collagen at the site of an injured blood vessel, which triggers the activation and aggregation of platelets. GPVI therefore has a role in so-called hemostasis, the process of stopping bleeding. However, excessive activation of the GPVI receptor can lead to the formation of pathological thrombi and thus to vascular occlusions, which impede blood flow to vital organs. A heart attack or stroke may result.

GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential

https://www.news-medical.net/health/GLP-1-receptor-agonists-in-Alzheimere28099s-disease-Emerging-off-label-neuroprotective-potential.aspx From reduced amyloid and neuroinflammation in experimental models to mixed cognitive outcomes in clinical trials, emerging evidence is testing whether GLP-1 receptor agonists can move beyond metabolic therapy to become meaningful treatments for Alzheimer’s disease. Type 2 diabetes (T2D) and insulin resistance are associated with an increased risk of cognitive decline and dementia, including Alzheimer’s disease (AD). This association has led researchers to investigate the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), such as semaglutide, for reducing dementia risk or slowing cognitive decline; however, a direct disease-modifying benefit in established AD remains unproven.4,5 GLP-1 RAs are approved for metabolic indications such as T2D and obesity rather than AD, so use specifically to prevent or treat AD remains off-label and investigational.3,4

Circadian Oncology: Timing, Cancer Treatment, and Patient Outcomes

https://www.news-medical.net/health/Circadian-Oncology-Timing-Cancer-Treatment-and-Patient-Outcomes.aspx Circadian rhythms influence cancer biology, treatment response, toxicity, and patient outcomes by affecting cellular processes, metabolism, immunity, sleep, and hormonal signaling. Aligning therapies with individual biological timing could improve cancer care, but clinical benefits vary by treatment, tumor type, sex, and circadian phase. The circadian clock regulates a wide range of biological processes that maintain cellular homeostasis. Disruptions to these internal rhythms may contribute to cancer development and progression, which has driven researchers to explore new therapeutic strategies like chronotherapy that align cancer treatment with individual circadian biology. In mammals, a central clock in the suprachiasmatic nucleus (SCN) of the hypothalamus coordinates peripheral clocks distributed throughout tissues and organs through neural, hormonal, metabolic, and temperature-related signals.

In a famous Blue Zone, daily movement was tied to fewer memory complaints

https://www.news-medical.net/news/20260813/In-a-famous-Blue-Zone-daily-movement-was-tied-to-fewer-memory-complaints.aspx A study of older adults living in Sardinia’s longevity-linked Blue Zone finds that daily movement, lower sedentary time, and confidence in physical and memory health are associated with fewer subjective memory concerns. A recent study published in the journal Experimental Gerontology suggests that objectively measured movement and participants’ perceptions of their physical health are associated with memory complaints in older adults. The findings linked greater daily movement, less sedentary behavior, better perceived physical health, and greater confidence in memory abilities with fewer subjective memory complaints. In this cohort, these factors were associated with a lower likelihood of reporting memory complaints in old age.

Epilepsy care must look beyond seizure control The Lancet Neurology + +... + +

Epilepsy care must look beyond seizure control The Lancet Neurology https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00291-7/fulltext?dgcid=raven_jbs_etoc_email Sep 2026 Volume 25Number 9p789-872 https://www.thelancet.com/journals/laneur/issue/vol25no9/PIIS1474-4422(26)X2007-5 Antiseizure medication use in pregnancy and the risk of poor fetal growth in the EURAP international registry: a prospective cohort study Prof Piero Perucca, MDa,b,c,d,e Send email to piero.perucca@unimelb.edu.au ∙ Charles B Malpas, PhDd,f,g ∙ Alexander Berry-Noronha, MBBSa,b ∙ Prof Susan P Walker, MDh,i ∙ Prof Tomas Kalincik, MDj,k ∙ Bibiane Moche Kamga, HSDl ∙ et al. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00216-4/fulltext?dgcid=raven_jbs_etoc_feature_laneur Safety and efficacy of guanabenz in early-childhood onset vanishing white matter: primary analysis of a single-arm, phase 1/2 trial Prof Marjo S van der Knaap, MDa,b,c Send email to ms.vanderknaap@amsterdamumc.nl ∙ Renate J Verbeek, MDa,b ∙ Romy J van Voorst, MSca,b ∙ Elia Gonzato, MSca,b,d ∙ Menno D Stellingwerff, MDa,b,e ∙ Marije M C Voermans, MSca,b ∙ et al. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(26)00241-3/abstract?dgcid=raven_jbs_etoc_feature_laneur

Questions AI cannot answer The Lancet Psychiatry + +... + +

Questions AI cannot answer The Lancet Psychiatry https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00242-7/fulltext?dgcid=raven_jbs_etoc_email Sep 2026 Volume 13Number 9p719-810, e12 https://www.thelancet.com/journals/lanpsy/issue/vol13no9/PIIS2215-0366(26)X2007-7 Incidence of systemic physical multimorbidity among people with schizophrenia-spectrum or bipolar-spectrum disorders compared with age-matched and sex-matched individuals in Queensland, Australia: a statewide, hospital cohort study Sean Halstead, MDa,b,d Send email to s.halstead@uq.edu.au ∙ Nicola Warren, PhDa,b,d ∙ Steve Kisely, DMedResa,b,d,e,f ∙ Urska Arnautovska, PhDa,b,d ∙ Mike Trott, PhDa,b,d ∙ Christoph U Correll, MDg,h,i,j,k ∙ et al. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00196-3/fulltext?dgcid=raven_jbs_etoc_feature_lanpsy Structural brain changes and clinical outcomes of patients with NMDA receptor encephalitis in Germany: a cross-sectional study Stephan Krohn, MDa,b ∙ Guido Cammà, MDa ∙ Wei Zhao, MDa ∙ Amy Romanello, MSca,b ∙ Katharina Wurdack, MDa ∙ Ole Jonas Böken, PhDa ∙ et al. https://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366(26)00191-4/fulltext?dgcid=raven_jbs_etoc_feature_lanpsy

HIV Resource Hub Expanded Website Now Available

https://hivresourcehub.org/?j=3040788&sfmc_sub=6992026&l=6498_HTML&u=76177631&mid=100006181&jb=0 The Health Resources and Services Administration’s (HRSA) HIV/AIDS Bureau (HAB) is pleased to announce that the expanded HIV Resource Hub (previously known as TargetHIV) launched in early August. As HAB’s one-stop shop for information, tools, and resources, the HIV Resource Hub offers new technical assistance resources, enhanced tagging and search functionality, and an HAB events calendar. Bookmark the HIV Resource Hub and check back often, as new resources and tools will be added to the website each month. To access the HIV Resource Hub website, please visit hivresourcehub.org. For any questions about the website, please reach out to your HAB project officer.

RAS-Targeted Strategies in Pancreatic Cancer: Progress and Future Directions Authors: Brian M. Wolpin, MD, MPH; Eileen M. O’Reilly, MD, FASCO; Zev A. Wainberg, MD

https://www.medscape.org/viewarticle/ras-targeted-strategies-pancreatic-cancer-progress-and-2026a100033c?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260813-OUS-HONC-ras-targeted-strategies-pancreatic-cancer-progress-and-2026a100033c-cta

AbCellera's nonhormonal menopause drug shows early success Exciting clinical trial results, a new gene therapy moves forward, safety concerns, and more led the news this week. Brought to you byDDN editorial team

AbCellera's nonhormonal menopause drug shows early success Exciting clinical trial results, a new gene therapy moves forward, safety concerns, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/abcellera-s-nonhormonal-menopause-drug-shows-early-success-17430 On Monday, AbCellera announced exciting results from their Phase 2 study testing ABCL635, an investigational antibody targeting the neurokinin 3 receptor (NK3R), in women with menopause. The drug achieved best-in-class results for hot flashes, reducing the mean number per day down from 10 to 3.5, compared to 8.8 in the placebo group. The drug also resulted in improved sleep with no serious or severe adverse events. With this data so far pointing to a better efficacy and safety profile compared to the currently available Veozah from Astellas Pharma and Lynkuet from Bayer, AbCellera’s drug could soon be a lucrative addition to the market, providing a better option for many women. “If validated in Phase 3, ABCL635 could offer a new treatment option with a more convenient dosing regimen and potentially less toxicity,” said JoAnn Pinkerton, Professor of Obstetrics and Gynecology at the University of Virginia School of Medicine in the press release. – Allison Whitten

Steps for Personalized and Collaborative Decision-Making in HER2-Mutated NSCLC Authors: Pasi Jänne, MD, PhD, FASCO; Soo-Ryum (Stewart) Yang, MD; Xiuning Le, MD, PhD

https://www.medscape.org/viewarticle/steps-personalized-and-collaborative-decision-making-her2-2026a10007ur?page=1&src=mkmcmr_driv_stan_mscpedu_260814-OUS-HONC-steps-personalized-and-collaborative-decision-making-her2-2026a10007ur-cta&uac=148436CN

Therapeutic Evolution in mHSPC: Analyzing Emerging Combinations and Outcomes Authors: Rana R. McKay, MD, FASCO; Alicia K. Morgans, MD, MPH, FASCO; David Morris, MD, FACS

https://www.medscape.org/viewarticle/therapeutic-evolution-mhspc-analyzing-emerging-combinations-2026a100087o?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260814-OUS-HONC-therapeutic-evolution-mhspc-analyzing-emerging-combinations-2026a100087o-cta

Canada’s Alcohol Consumption Guidance: A Roundtable Discussion Jürgen Rehm, PhD; Peter R. Butt, MD

https://www.medscape.com/viewarticle/canadas-alcohol-consumption-guidance-roundtable-discussion-2026a1000qq4?ecd=wnl_edit_tpal_etid8599249&uac=148436CN&impID=8599249

Expert Panel Decision Framework: Progressive Strategies for Managing HER2-Mutated Advanced NSCLC Authors: Charu Aggarwal, MD, MPH; Herbert H. Loong, MBBS, FRCP; Umberto Malapelle, PhD

https://www.medscape.org/viewarticle/expert-panel-decision-framework-progressive-strategies-2026a1000diy?page=1&src=mkmcmr_driv_stan_mscpedu_260814-OUS-HONC-expert-panel-decision-framework-progressive-strategies-2026a1000diy-cta&uac=148436CN

Managing Endometrial Cancer: Unpacking the Data Behind the Latest Immunotherapy Advancements Authors: Ana Oaknin, MD, PhD; Domenica Lorusso, MD, PhD

https://www.medscape.org/viewarticle/managing-endometrial-cancer-unpacking-data-behind-latest-2026a1000bh0?page=1&uac=148436CN&src=mkmcmr_driv_cust_mscpedu_260815-OUS-HONC_NOLO-managing-endometrial-cancer-unpacking-data-behind-latest-2026a1000bh0-cta

Region 6 Access to Care Community of Practice Quarterly Event Registration: Access to Care Community of Practice Registration is Live!

Access to Care Community of Practice Registration is Live! The Region 6 Office of the Assistant Secretary for Health (OASH) is excited to announce the launch of the Access to Care Community of Practice! This is a free event and is open to all partners interested in joining and participating in this new regional peer-to-peer learning initiative. Future meetings will be held on a quarterly basis and will feature innovations in care delivery in rural or low-access settings. Please join us for the inaugural session on https://events.gcc.teams.microsoft.com/event/0ffaa37c-4302-44c3-9628-2aeffc28c594@d58addea-5053-4a80-8499-ba4d944910df?source=copyLinkLegacyShareLinkDialog&utm_medium=email&utm_source=govdelivery September 9th from 1 - 2 PM CT / 12 - 1 PM MT! During the September 9th event, Tom Morris, the Associate Administrator for Rural Health Policy at HRSA, will present on the Federal Office of Rural Health Policy’s (FORHP) current priorities, initiatives, and funding opportunities to strengthen health care in rural communities. He will highlight key rural health challenges—including hospital financial instability, workforce shortages, maternity care access, behavioral health, and chronic disease—while showcasing federal programs, technical assistance, policy efforts, and partnerships designed to improve access to care and support rural hospitals and clinics. The presentation also outlines upcoming funding opportunities, new resources, and strategies for helping rural communities leverage federal programs and build sustainable health care networks.

H3 K27M-Mutant Glioma: Advancing Clinical and Patient-Centered Care Across the Age Spectrum Authors: Patrick Y. Wen, MD; Stephen Bagley, MD, MSCE; Carl Koschmann, MD

https://www.medscape.org/viewarticle/h3-k27m-mutant-glioma-advancing-clinical-and-patient-2026a1000qxm?page=1

SBRT vs IMRT: Better for Bowel Symptoms, Not Cancer Control Edited by Amy Norton

https://www.medscape.com/viewarticle/sbrt-vs-imrt-better-bowel-symptoms-not-cancer-control-2026a1000rud?src=

This Is What mRNA Vaccines May Actually Do in the Body Edited by Medscape Staff

https://www.medscape.com/s/viewarticle/this-what-mrna-vaccines-may-actually-do-body-2026a1000rr9?src=

Dexrazoxane May Preserve Left Ventricular Function in Cancer Survivors Edited by Katie Lennon

https://www.medscape.com/viewarticle/dexrazoxane-may-preserve-left-ventricular-function-cancer-2026a1000rvy?src= Dexrazoxane was associated with preserved left ventricular (LV) systolic function in childhood cancer survivors treated with doxorubicin in a new analysis. Among 895 patients, those receiving dexrazoxane showed better LV fractional shortening and reduced incidence of LV dysfunction, particularly in high-risk groups where rates approached those of moderate-risk patients.

Metabolic, Autoimmune Links Seen in Symptomatic Sclerosing Mesenteritis Edited by Vinod Rane, BS Pharm

https://www.medscape.com/viewarticle/metabolic-autoimmune-links-seen-symptomatic-sclerosing-2026a1000rjo?src= Patients with symptomatic sclerosing mesenteritis (SM) presented with abdominal pain and had conditions such as immunoglobulin G4 (IgG4)-related disease, abdominal and/or pelvic malignancies, or metabolic syndrome.

Navigating Puberty A Time of Changes and Challenges

https://newsinhealth.nih.gov/2026/08/navigating-puberty Puberty is a normal, natural part of growing up. It’s also a time of huge change, when children’s bodies mature. With hormones surging, early adolescents may have mood, energy, and sleep changes. They may feel self-conscious about how they look.

Finding an Eye Doctor

Finding an Eye Doctor Seeing an eye doctor is the best way to stay on top of your eye health — and eye doctors aren’t just for people who need glasses or contacts. Many common eye diseases don’t have any early warning signs, so getting an eye exam is the only way to be sure your eyes are healthy. https://www.nei.nih.gov/eye-health-information/healthy-vision/finding-eye-doctor

Tracking diets via wastewater

https://www.nih.gov/news-events/nih-research-matters/tracking-diets-wastewater At a Glance Measuring DNA from food in wastewater could provide snapshots of dietary patterns. Monitoring these patterns could be a powerful tool for informing nutrition policy.

Lung Cancer—Patient Version

https://www.cancer.gov/types/lung Lung cancer includes two main types: non-small cell lung cancer and small cell lung cancer. Smoking causes most lung cancers, but nonsmokers can also develop lung cancer. Explore the links on this page to learn more about lung cancer treatment, prevention, screening, statistics, research, clinical trials, and more.

Overview of Psoriasis

https://www.niams.nih.gov/health-topics/psoriasis Psoriasis is a chronic (long-lasting) disease in which the immune system becomes overactive, causing skin cells to multiply too quickly. Patches of skin become scaly and inflamed, most often on the scalp, elbows, or knees, but other parts of the body can be affected as well. Scientists do not fully understand what causes psoriasis, but they know that it involves a mix of genetics and environmental factors.

Rethinking Inflammation and ASCVD: Four Lessons From the ZEUS Trial

https://www.medscape.com/viewarticle/rethinking-inflammation-and-ascvd-four-lessons-zeus-trial-2026a1000rlm?ecd=WNL_trdalrt_pos1_ous_260814_etid8596530&uac=148436CN&impID=8596530

Recommended CME For You +++++ ++++ (-)+

Advanced Neuroendocrine Tumors: Integrating Emerging Targeted Therapies Into Patient Care CME https://www.medscape.org/viewarticle/1002665?src=mkmcmr_driv_invit_mscpedu&uac=148436CN Optimizing Outcomes for Thyroid Cancer With NTRK Gene Fusions: Precision Care, Patient Impact CME https://www.medscape.org/viewarticle/1002660?src=mkmcmr_driv_invit_mscpedu&uac=148436CN Managing Patients With HR+/HER2- EBC: Assess Your Knowledge CME https://www.medscape.org/viewarticle/managing-patients-hr-her2-ebc-assess-your-knowledge-2025a1000ier?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Targeted Therapies for NSCLC: Where Are We Today? CME https://www.medscape.org/viewarticle/1002896?src=mkmcmr_driv_invit_mscpedu&uac=148436CN PTEN Deficiency in Prostate Cancer: Biology, Prognosis, and Therapeutic Relevance CME https://www.medscape.org/viewarticle/pten-deficiency-prostate-cancer-biology-prognosis-and-2025a1000rqh?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN NF-1 Associated Plexiform Neurofibromas in Adults: Which Patients Could Benefit From Emerging Systemic Therapies? CME https://www.medscape.org/viewarticle/1003044?src=mkmcmr_driv_invit_mscpedu&uac=148436CN High-Risk HR-Positive, HER2-Negative Early Breast Cancer: Latest Updates From the European Oncology Congress CME https://www.medscape.org/viewarticle/high-risk-hr-positive-her2-negative-early-breast-cancer-2025a1000udm?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Expanding the Frontiers of HER2-Targeted Therapy in Gynecologic Cancers CME https://www.medscape.org/viewarticle/expanding-frontiers-her2-targeted-therapy-gynecologic-2025a1000udv?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN Building Consensus in Nonmelanoma Skin Cancer Care: Applying Emerging Science and Best Practices CME Latest Advances in mHSPC: An Update From Berlin 2025 CME https://www.medscape.org/viewarticle/latest-advances-mhspc-update-berlin-2025-2025a1000vlk?page=1&src=mkmcmr_driv_invit_mscpedu&uac=148436CN

Mitochondrial DNA and neurofilament release as Parkinson’s phenotypes in midbrain organoids Sonia Sabate-Soler [1,2]ORCID iD , Isabel Rosety [1]ORCID iD , Gemma Gomez-Giro [1]ORCID iD , Jenny Ghelfi [2]ORCID iD , Soraya Hezzaz [2]ORCID iD , Anne Grünewald [2]ORCID iD , Jens C. Schwamborn [1,2]ORCID iD , Javier Jarazo* [1]

https://www.academia.edu/3071-4087/2/2/10.20935/AcadNeurosci8295 Introduction: Parkinson’s disease (PD) prevalence keeps growing worldwide, with growing numbers and considerable societal and economic concerns. This study aimed to evaluate the use of microglia-containing midbrain organoids as PD patient-specific systems for the detection of extracellular disease biomarkers. Materials and methods: We used the cell culture supernatant from healthy control and patient-specific organoids to measure Neurofilament light chain (NfL) levels via ELISA and to study mitochondrial DNA phenotypes through digital polymerase chain reaction (PCR). Organoid tissue was used for immunofluorescence staining and quantification of alpha-synuclein and glial fibrillary acidic protein (GFAP) levels. Results: Organoids generated from the PD patient line released higher levels of NfL and mitochondrial DNA into the medium. Furthermore, immunofluorescence staining of PD patient-specific organoids showed higher levels of phosphorylated alpha-synuclein as well as GFAP. Conclusions: Alterations in NfL levels and mitochondrial DNA homeostasis can be measured in the organoid supernatant and are particularly suitable as disease biomarkers and for high-throughput screening approaches. https://www.academia.edu/journals/academia-neuroscience-and-brain-research/articles?source=journal-top-nav

Interprofessional Approach to Adverse Event Care for the Patient With High-Risk Hormone Receptor-Positive/HER2-Negative Early Breast Cancer Authors: Jonathan Malara, PharmD, BCOP; Nelli Zafman, CRNP, MSN, AOCNP

https://www.medscape.org/viewarticle/interprofessional-approach-adverse-event-care-patient-high-2026a1000gez?page=1&src=mkmcmr_driv_stan_mscpedu_260814-OUS-HONC-interprofessional-approach-adverse-event-care-patient-high-2026a1000gez-cta&uac=148436CN

Does High-Dose Vitamin D3 Supplementation Improve CRC Survival? Edited by Katie Lennon +++ +++

Does High-Dose Vitamin D3 Supplementation Improve CRC Survival? Edited by Katie Lennon https://www.medscape.com/viewarticle/does-high-dose-vitamin-d3-supplementation-improve-crc-2026a1000qib?ecd=mkm_ret_260814_mscpmrk-OUS_ICYMI_etid8586335&uac=148436CN&impID=8586335 High-dose vitamin D3 supplementation added to standard chemotherapy plus bevacizumab does not improve progression-free survival (PFS) compared with standard-dose vitamin D3 in patients with previously untreated metastatic colorectal cancer (mCRC). Among 455 randomized patients, median PFS was 11.8 months in the high-dose group vs 10.3 months in the standard-dose group, with no significant differences in objective response rates or overall survival. Coronary Artery Calcium Scoring May Refine Heart Risk Estimate and Statin Decisions Edited by Archita Rai https://www.medscape.com/viewarticle/coronary-artery-calcium-scoring-may-refine-heart-risk-2026a1000qhq?ecd=mkm_ret_260814_mscpmrk-OUS_ICYMI_etid8586335&uac=148436CN&impID=8586335 Adding coronary artery calcium (CAC) scoring to risk estimates helped better identify adults at lower and higher risk for atherosclerotic cardiovascular disease (ASCVD) events. People with no detectable CAC had lower observed risk, while those with CAC had higher observed risk, especially when the decision about starting a statin was uncertain. The Coming ‘Tsunami’: Cardiac Effects of Cancer Therapy Carolyn Brown https://www.medscape.com/viewarticle/coming-tsunami-cardiac-effects-cancer-therapy-2026a1000qbr?ecd=mkm_ret_260814_mscpmrk-OUS_ICYMI_etid8586335&uac=148436CN&impID=8586335 Higher Protein Intake Not Linked to Kidney Function Decline in Middle-Aged and Older Adults https://www.medscape.com/viewarticle/higher-protein-intake-not-linked-kidney-function-decline-2026a1000qt2?ecd=mkm_ret_260814_mscpmrk-OUS_ICYMI_etid8586335&uac=148436CN&impID=8586335 Opinions Shifting on Coupling Metformin and Exercise https://www.medscape.com/viewarticle/opinions-shifting-coupling-metformin-and-exercise-2026a1000qg7?ecd=mkm_ret_260814_mscpmrk-OUS_ICYMI_etid8586335&uac=148436CN&impID=8586335 Scientists May Have a New Explanation for Excessive Sweating https://www.medscape.com/viewarticle/scientists-may-have-new-explanation-excessive-sweating-2026a1000qr1?ecd=mkm_ret_260814_mscpmrk-OUS_ICYMI_etid8586335&uac=148436CN&impID=8586335

One population, many risks: rethinking youth suicide prevention in the Americas The Lancet Regional Health – Americas +... ++

One population, many risks: rethinking youth suicide prevention in the Americas The Lancet Regional Health – Americas https://www.thelancet.com/journals/lanam/issue/vol60nonull/PIIS2667-193X(26)X2005-1 Superficial parasternal intercostal plane block with ropivacaine versus placebo for opioid exposure after cardiac surgery (EPOCH CardioLink-10): a multicentre, double-blind, randomised trial Ahmad Allia,b,c,d,z ∙ C. David Mazera,b,c,d,e,f,z Send email to david.mazer@unityhealth.to ∙ Fallon Dennisb,f,g,z ∙ Hwee Teohb,g,h,z ∙ Kyle China,b ∙ Adrian Quanb,g ∙ et al. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00138-9/fulltext?dgcid=raven_jbs_etoc_feature_lanam The burden of oral disorders in Latin America and Caribbean countries from 1990 to 2023 and projections until 2050: a systematic analysis for the Global Burden of Disease Study 2023 GBD 2023 Latin America and Caribbean Oral Disorders Collaborators https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(26)00147-X/fulltext?dgcid=raven_jbs_etoc_feature_lanam

Skin diseases: beyond the visible The Lancet +... + +

Skin diseases: beyond the visible The Lancet https://www.thelancet.com/journals/lancet/issue/vol408no10555/PIIS0140-6736(26)X2030-X Retroperitoneal fibrosis Prof Augusto Vaglio, MD PhDa,c Send email to augusto.vaglio@unifi.it ∙ Francesco Peyronel, MDb ∙ Prof Ingeborg M Bajema, MD PhDd ∙ Francesco Pegoraro, MD https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00037-1/abstract?dgcid=raven_jbs_etoc_feature_lancet Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies Prof Thierry Passeron, MDa,b Send email to passeron@unice.fr ∙ Vimal H Prajapati, MDc,d,e,f,g,h ∙ Raja K Sivamani, MDi,j,k,l ∙ Prof Khaled Ezzedine, MDm ∙ Prof Nanja van Geel, MDn ∙ Iltefat Hamzavi, MDo ∙ et al. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00896-2/fulltext?dgcid=raven_jbs_etoc_feature_lancet

FDA Advisory Board’s Concerns About New Duchenne Drug, Brain Fog in Immune Thrombocytopenia by Peter Ciszewski| Published on: Aug 8, 2026

https://checkrare.com/fda-advisory-boards-concerns-about-new-duchenne-drug-brain-fog-in-immune-thrombocytopenia/

Follow-Up Data of Safusidenib in Patients With IDH-Mutant Gliomas by Madaline Spencer| Published on: Aug 14, 2026

Follow-Up Data of Safusidenib in Patients With IDH-Mutant Gliomas by Madaline Spencer| Published on: Aug 14, 2026 Alexandra Miller, MD, PhD, Chief of Neuro-Oncology and Co-Director of the Brain and Spine Tumor Center at the Perlmutter Cancer Center at NYU Langone Health, discusses follow-up data on the safety and efficacy of safusidenib in patients with IDH-mutant gliomas. https://checkrare.com/follow-up-data-of-safusidenib-in-patients-with-idh-mutant-gliomas/

2025 Winter Conference Update: Novel and Emerging Treatment Strategies for Breast Cancer Authors: François-Clément Bidard, MD, PhD; Mothaffar F. Rimawi, MD, FACP; Nadia Harbeck, MD, PhD

https://www.medscape.org/viewarticle/winter-conference-update-novel-and-emerging-treatment-2026a100030r?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_260811-OUS-HONC-winter-conference-update-novel-and-emerging-treatment-2026a100030r-cta

Revisiting the Outbreak of Pediatric Hepatitis: A Second Look at Acetaminophen

https://www.medscape.com/viewarticle/revisiting-outbreak-pediatric-hepatitis-second-look-2026a1000qee?ecd=WNL_trdalrt_pos1_ous_260812_etid8590112&uac=148436CN&impID=8590112

Improving Parkinson’s disease treatment

Improving Parkinson’s disease treatment At a Glance Researchers identified a drug candidate that enhanced effectiveness and reduced side effects of the standard Parkinson’s disease treatment in animal models. If the drug candidate proves effective in people, it could be an effective way to improve treatment for Parkinson’s disease. https://www.nih.gov/news-events/nih-research-matters/improving-parkinsons-disease-treatment

Immune cells cross blood-brain barrier during human aging

Immune cells cross blood-brain barrier during human aging At a Glance Researchers found that some of the brain’s immune cells are replaced by immune cells from bone marrow as people age. The findings suggest that scientists might one day be able to use immune cells born outside the brain to deliver therapies for brain disorders. https://www.nih.gov/news-events/nih-research-matters/immune-cells-cross-blood-brain-barrier-during-human-aging

Childhood screen detects mental health risks

Childhood screen detects mental health risks At a Glance Screening for home and family stresses may help identify children at risk for depression and sleep disorders that traditional adversity screening misses. This type of screening could be used to identify and intervene with children at risk of mental health conditions. https://www.nih.gov/news-events/nih-research-matters/childhood-screen-detects-mental-health-risks

Voices in Care: Multidisciplinary and Patient Perspectives on Advanced/Recurrent Endometrial Cancer Authors: Eva-Maria Strömsholm; Rebecca Kristeleit, MBChB, MRCP, PhD; Domenica Lorusso, MD, PhD; Antonio González-Martín, MD, PhD; Claire Lusted, ANP

https://www.medscape.org/viewarticle/voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui?page=1&src=mkmcmr_driv_stan_mscpedu_260811-OUS-HONC-voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui-cta&uac=148436CN